Turns daily psychiatric pills into monthly or quarterly injections using a patented encapsulation process at one facility in Wilmington, North Carolina.
Alkermes takes psychiatric drugs like olanzapine and aripiprazole and encapsulates them inside tiny polymer shells at its facility in Wilmington, North Carolina, turning a daily pill into an injection a patient receives once a month or once a quarter. The FDA approves not the drug molecule but the specific encapsulation geometry and sterile production process running on the Wilmington equipment, so the regulatory approval and the factory are effectively the same thing. Because any competitor holding the identical compound and polymer chemistry still has to run a full facility-specific validation from scratch — a process that takes years and cannot be accelerated with money — the Wilmington building functions as both the manufacturing asset and the competitive barrier at once. If those production lines ever failed an FDA inspection badly enough to trigger a shutdown, every product approval tied to them would collapse simultaneously, and there is no second facility that could step in, because no second facility has ever been validated to run these processes.
How does this company make money?
The company earns revenue each time its long-acting injectable drugs are sold to distributors and healthcare systems. It also collects manufacturing fees and royalties from Janssen for producing the Invega injectable line at the Wilmington facility. On top of that, it receives milestone payments and licensing fees from other companies that use its NanoCrystal and LinkeRx drug delivery technologies.
What makes this company hard to replace?
Patients who move from a long-acting injectable back to daily pills face a much higher risk of missing doses and seeing their treatment fail — there is no oral medication that reliably produces the same compliance outcomes. Healthcare providers who switch products must retrain staff on different injection techniques and dosing schedules. And because the FDA treats each microsphere formulation as a unique approved product, pharmacies cannot automatically substitute a generic the way they can with ordinary pills.
What limits this company?
Every new drug formulation must be tested and approved on the exact equipment in Wilmington that will produce it, and that process takes years per formulation. The company can only make as many approved products as those specific sterile lines allow, and adding more capacity means starting that long validation process all over again.
What does this company depend on?
The company cannot operate without FDA approvals tied to each specific injectable formulation, a steady supply of the active drug compounds olanzapine and aripiprazole, the specialized microsphere encapsulation equipment running inside the Wilmington facility, the NanoCrystal and LinkeRx platform technologies that underpin its formulations, and DEA licenses that permit it to handle and manufacture Schedule II controlled substances.
Who depends on this company?
Schizophrenia patients receiving Aristada injections rely on this facility for a medication they cannot simply replace with a daily pill without risking treatment failure and hospitalization. Healthcare providers who administer monthly injectables have no equivalent long-acting alternative to turn to if supply stopped. Janssen, the pharmaceutical company, depends on the Wilmington facility to manufacture its Invega injectable products under a partnership agreement.
How does this company scale?
Once the microsphere encapsulation process is developed for one psychiatric compound, the same underlying technology can be applied to additional molecules — so the platform itself can expand. What does not scale easily is the physical manufacturing: each new drug formulation still needs years of validation on the Wilmington lines before it can be sold, so the factory walls set a hard limit on how fast growth can happen.
What external forces can significantly affect this company?
The DEA sets annual production quotas for controlled substances, which can cap how much the company is allowed to manufacture regardless of demand. Because the company is domiciled in Ireland, it must also satisfy the European Medicines Agency's approval requirements to access global markets. Changes to what Medicare or commercial health insurers will pay for long-acting injectables could directly reduce how much revenue the company collects per dose.
Where is this company structurally vulnerable?
If the FDA found serious problems at the Wilmington facility — enough to issue a shutdown order or a consent decree — every single product the company sells would lose its legal manufacturing basis at the same moment, because every approval lives inside that one building. There is no backup facility that could step in.
Sign in to view price data.
Sign inStructural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph